Investegate | Company Announcement
Investegate announcements from Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
United States San Diego Fosun Pharma Vinod Balachandran Roche Group Memorial Sloan Kettering Cancer Center
Source: investegate.co.uk